EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of Midazolam Plasma Concentrations in ARDS Patients with and Without ECMO Support—Prospective Observational Pilot Study

Marek Grochla iD, Marcin Basiak iD, Bogusław Okopień iD, Ewa Trejnowska, Piotr Knapik

Life · 10.07.2026 · 16 (7) · 1144

DOI: 10.3390/life16071144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 10.07.2026. Verfasst von Marek Grochla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Therapy in Zabrze, Medical University of Silesia in Katowice, Ul. Marii Skłodowskiej-Curie 9, 41-800 Zabrz…. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Polish National Science Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients undergoing ECMO therapy have a much higher need for drug therapy due to the increased volume of distribution and deeper levels of sedation. The influence of ECMO support on the achieved midazolam concentrations is unknown. Materials and Methods: This prospective, single-center study was conducted between October 2022 and December 2024. All mechanically ventilated patients with an FiO2 over 0.6 or requiring VV ECMO for respiratory support were included. Patients younger than 18 years, patients without midazolam infusion, and patients with a do-not-resuscitate protocol were excluded. Patients were divided into a group requiring ECMO therapy (group A, n = 14, 88 measurements) and a group receiving conventional respiratory support (group B, n = 11, 44 measurements). Mean daily doses of midazolam and achieved midazolam concentrations were compared. Chi-squared tests, Mann–Whitney U tests, Pearson’s r correlation, and Spearman’s rank correlation were used to assess statistical significance between groups, where appropriate.

Results

In terms of demographic data, patients in group A were comparable to group B, except that patients in group A had a lower BMI (25.7 ± 5.1 kg/m2 vs. 34.0 ± 10.1 kg/m2, p = 0.014). Midazolam requirements in the ECMO group were higher (3.6 ± 1.6 mg/kg vs. 1.8 ± 1.3 mg/kg, p < 0.001). Despite this, midazolam plasma concentrations in both groups were comparable, and only midazolam metabolites were found to be higher in group A (60 ± 72 ug/L vs. 22 ± 19 ug/L; p < 0.001).

Conclusions

The use of probably higher doses of midazolam does not translate into higher plasma midazolam concentrations in ECMO patients.

Schlagwörter

Stichwörter der Autor:innen

ARDSECMOICUdrug monitoringmidazolam

Autor:innen und Institutionen

  • Department of Anesthesiology and Intensive Therapy in Zabrze, Medical University of Silesia in Katowice, Ul. Marii Skłodowskiej-Curie 9, 41-800 Zabrze, Poland.
  • Department of Internal Medicine and Clinical Pharmacology in Katowice, Medical University of Silesia in Katowice, Ul. Medyków 14, 40-752 Katowice, Poland.

ORCID-Profile: Marek Grochla, Marcin Basiak, Bogusław Okopień

Förderung

  • National Science Centre
  • Polish National Science Centre

Zitieren

APA

Grochla, M., Basiak, M., Okopień, B., Trejnowska, E., & Knapik, P. (2026). Comparison of Midazolam Plasma Concentrations in ARDS Patients with and Without ECMO Support—Prospective Observational Pilot Study. Life, 16(7), 1144. https://doi.org/10.3390/life16071144

Vancouver

Grochla M, Basiak M, Okopień B, Trejnowska E, Knapik P. Comparison of Midazolam Plasma Concentrations in ARDS Patients with and Without ECMO Support—Prospective Observational Pilot Study. Life. 2026;16(7):1144. doi:10.3390/life16071144

BibTeX
@article{Grochla2026,
  author = {Grochla, Marek and Basiak, Marcin and Okopień, Bogusław and Trejnowska, Ewa and Knapik, Piotr},
  title = {Comparison of Midazolam Plasma Concentrations in ARDS Patients with and Without ECMO Support—Prospective Observational Pilot Study},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {1144},
  doi = {10.3390/life16071144}
}
Kostenlos starten →